HYHaijiao Yan

Haijiao Yan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haijiao Yan has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Jun Wu

    Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, China

    3 shared publications
  • Fang Wei

    Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China

    2 shared publications
  • Wensong Liu

    Soochow Univ, Dept Hepatobiliary Surg, Affiliated Hosp 3, Changzhou 213003, Peoples R China

    2 shared publications
  • Ye Zhang

    Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, China

    2 shared publications
  • Ye Zhang

    Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China

    2 shared publications
  • Bo Jiang

    Department of Thoracic Surgery, the Third Affiliated Hospital of Soochow University, Changzhou, China

    1 shared publication

Latest Publications

  • PODXL2 Promotes Cholangiocarcinoma Progression via Interactions with Ezrin and Activation of the MAPK/ERK1/2 and PI3K/AKT Signaling Pathways

    by Yu Meng, Ye Zhang, Fang Wei, Ruilin Zhang, Zekang Li, Yueping Shen, Haijiao Yan, Jun Wu

    Background Cholangiocarcinoma (CCA), an aggressive malignancy of the biliary epithelium, is associated with poorclinical outcomes. The lack of distinct early-stage symptoms often leads to a delayed diagnosis. Therefore, theidentifi cation of reliable biomarkers and therapeutic targets is crucial for improving patient outcomes. Althoughpodocalyxin-like protein 2 (PODXL2) is implicated in other malignancies, its role in CCA remains underexplored. Weaimed to elucidate the functional role of PODXL2 in CCA and determine its prognostic signifi cance in patientoutcomes. Methods PODXL2 expression was analyzed by immunohistochemistry on tissue microarrays. In vitro functionalassays were performed in HuCCT1 cells with PODXL2 knockdown or overexpression. Scratch wound healing andTranswell assays evaluated cell migration and invasion. Immunofl uorescence staining assessed cytoskeletalremodeling. The underlying mechanisms were explored through co-immunoprecipitation, western blot, andbioinformatic analyses. Results Immunohistochemistry revealed markedly elevated PODXL2 expression in CCA tissues compared with that inadjacent normal tissues, and high PODXL2 levels were inversely correlated with overall survival. Functional assaysdemonstrated that PODXL2 overexpression promoted CCA cell migration and invasion, accompanied by cytoskeletalremodeling and altered F-actin distribution. Mechanistically, PODXL2 activated MAPK/ERK1/2 and PI3K/AKT signaling,enhancing the expression of MMP1, MMP2, and MMP9. Additionally, PODXL2-induced migration, invasion, anddownstream signaling activation were attenuated following the knockdown of Ezrin. Conclusions PODXL2 is signifi cantly overexpressed in CCA and associated with adverse clinical outcomes. Throughinteractions with Ezrin, PODXL2 promotes CCA cell migration and invasion via MAPK/ERK1/2 and PI3K/AKT pathwayactivation. These fi ndings support PODXL2 as a potential diagnostic biomarker and therapeutic target in CCA.


  • Open Access

    S100 Calcium-Binding Protein P and Cathepsin E as Key Mediators in Pancreatic Cancer Tumorigenesis

    by Yu Meng, Qian Deng, Ye Zhang, Fang Wei, Jun Wu, Haijiao Yan

    Background/Objectives: Pancreatic cancer (PC) remains one of the deadliest malignancies, with challenges that hinder early detection and few actionable molecular targets. In this study, we aimed to identify biomarkers predictive of PC to support its diagnosis and treatment. Methods: Proteins from formalin-fixed, paraffin-embedded pooled samples of PC (n = 15; 5 pools) and chronic pancreatitis (n = 10; 5 pools) tissues were analyzed via label-free quantitative proteomics using liquid chromatography-tandem mass spectrometry. Immunohistochemistry (IHC) was performed on PC tissue microarrays to assess S100 calcium-binding protein P (S100P) and cathepsin E (CTSE) expression (IHC evaluable pairs: n = 78 for S100P; n = 82 for CTSE). Transwell invasion assays were conducted to evaluate the effects of these proteins on PC cell invasiveness, and Western blotting was used to validate protein expression and elucidate associated molecular mechanisms. Results: Both S100P and CTSE were overexpressed in PC tissues compared with those in adjacent normal tissues. Elevated S100P expression correlated with poor prognosis, whereas higher CTSE expression predicted favorable outcomes; both served as independent prognostic factors in PC. Functionally, S100P promoted PC cell invasion, whereas CTSE suppressed it. Mechanistically, both proteins appeared to regulate epithelial–mesenchymal transition (EMT) and invasive capacity through activation or inhibition of the phosphoinositide 3-kinase (PI3K)–protein kinase B (AKT) signaling pathway. Conclusions: Elevated expression of S100P and CTSE in PC tissues serves as independent indicators in our model of patient survival. Both proteins regulate EMT and invasion, potentially via the PI3K–AKT pathway, and hold significant promise as prognostic biomarkers and therapeutic targets in PC.


  • Open Access

    The Role and Function of Non-Coding RNAs in Cholangiocarcinoma Invasiveness

    by Yu Meng, Fang Wei, Ye Zhang, Wenting He, Haijiao Yan, Jun Wu

    Cholangiocarcinoma (CCA) is an aggressive tumor that originates from the epithelial cells of the bile duct and has the ability to metastasize to the liver or lymph nodes at an early stage. CCA metastasis represents a complex, multi-stage cascade process. Among these stages, the acquisition of invasiveness by CCA cells is a critical prerequisite for metastatic progression. Elucidating the molecular mechanisms driving CCA cell invasiveness is critical for advancing our knowledge in this field. Emerging evidence highlights the critical role of non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). These molecules orchestrate key processes such as the epithelial–mesenchymal transition (EMT), as well as the migration and invasion of CCA cells. Collectively, these processes ultimately drive tumor progression. This review comprehensively synthesizes the expression, biogenesis, interactions, signaling pathways, and functional mechanisms of ncRNAs in the invasiveness of CCA. Furthermore, the review discusses potential clinical applications of ncRNAs, including their roles as diagnostic tools, therapeutic targets, and prognostic markers. These investigations offer novel insights and evidence for identifying early metastasis in CCA, developing specific therapeutic strategies, and enhancing drug resistance.


  • The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma

    by Ye Zhang, Hai-Jiao Yan, Jun Wu

    Cholangiocarcinoma (CCA) is an epithelial cancer distinguished by bile duct cell differentiation and is also a fibroproliferative tumor. It is characterized by a dense mesenchyme and a complex tumor immune microenvironment (TME). The TME comprises both cellular and non-cellular components. The celluar component includes CCA cells, immune cells and mesenchymal cells represented by the cancer-associated fibroblasts (CAFs), while the non-cellular component is represented by mesenchymal elements such as the extracellular matrix (ECM). Recent studies have demonstrated the important role of the TME in the development, progression, and treatment resistance of CCA. These cell-associated prognostic markers as well as intercellular connections, may serve as potential therapeutic targets and could inspire new treatment approaches for CCA in the future. This paper aims to summarize the current understanding of CCA's immune microenvironment, focusing on immune cells, mesenchymal cells, ECM, intercellular interactions, and metabolism within the microenvironment.


  • Circulating tumor cells in gastric cancer: developments and clinical applications

    by Qian Deng, Bo Jiang, Haijiao Yan, Jun Wu, Zhenzhen Cao

    Circulating tumor cells (CTCs), which are shed from primary tumor or metastatic sites into the bloodstream and subsequently seed into distant tissues, are considered as the precursors of metastases. Gastric cancer (GC) is a highly heterogeneous malignant tumor. With regard to the diagnosis of GC, secondary pathological biopsy is difficult, while invasive examination is harmful to patients. In recent years, CTCs have made great progress in tumor diagnosis, prognosis prediction, efficacy detection and treatment guidance, but the research on the role of CTCs in GC remains limited. The following sections review the landmark studies demonstrating the technical approaches of CTCs monitoring in the field of GC. Moreover, we highlight the clinical application of CTCs numbers and phenotypes in monitoring the therapeutic efficacy and judging patient prognosis by sequential blood analyses.


  • MicroRNA-708 inhibits the proliferation and chemoresistance of pancreatic cancer cells

    by Wensong Liu, Yunjie Lu, Dong Zhang, Longqing Shi, Guangchen ZU, Haijiao Yan, Donglin Sun

    Pancreatic cancer is one of the most aggressive malignancies with poor prognosis and high mortality. Recent studies showed that microRNAs are dysregulated and involved in the initiation and progression of pancreatic cancer. In this study, we found that miR-708 was significantly downregulated in pancreatic cancer tissues and cell lines. Lentivirus-mediated overexpression of miR-708 could significantly inhibit the proliferation and invasion, while enhanced chemosensitivity to gemcitabine in both Panc-1 and SW1990 cells. Luciferase reporter assay showed that miR-708 bound the 3’-untranslated region of survivin and suppressed the expression of survivin in pancreatic cancer cells. In pancreatic cancer tissues, survivin protein was highly expressed and negatively correlated with miR-708 expression. Furthermore, the restoration of survivin expression could partially antagonize proliferation inhibition and apoptosis induction by miR-708 in pancreatic cancer cells. The Panc-1 cells with overexpression of miR-708 also showed decreased proliferation capability in nude mouse model compared with parental cells. In conclusion, our results suggest that miR-708 inhibits pancreatic cancer and could be a novel potential candidate to treat pancreatic cancer.


  • Retracted
    Open Access

    MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway

    by Wei Zhou, Yongfeng Li, Shanmiao Gou, Jiongxin Xiong, Heshui Wu, Chunyou Wang, Haijiao Yan, Tao Liu

    MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway


  • Open Access

    siRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellular carcinoma cells

    by Wensong Liu, Feng Zhu, Yong Jiang, Donglin Sun, Bo Yang, Haijiao Yan

    Survivin has become an attractive anticancer therapeutic target due to its important role in tumor cell viability and its selective expression in tumor cells. In the present study, we constructed a recombinant siRNA plasmid vector against survivin and stably transfected it into HepG2 and SMMC‑7721 hepatocellular carcinoma cells in vitro. Semi-quantitative RT-PCR and western blotting were used to determine the expression of survivin mRNA and protein, respectively. Tumor cell proliferation was assessed by trypan blue exclusion. We evaluated the change in caspase-3 activity, and the rate of cell apoptosis and the cell cycle distribution were analyzed by flow cytometry. Assessment of chemosensitivity was carried out by MTT assay. The results showed that transfection of survivin siRNA caused a significant inhibition of survivin mRNA and protein expression which was associated with cell growth inhibition, specific G0/G1 phase arrest, increased caspase-3 activity and enhanced chemosensitivity to cisplatin in both HCC cell lines. We suggest that suppression of survivin expression by RNAi attenuates the malignant phenotype of hepatocellular carcinoma cells, and may provide a novel approach for anticancer gene therapy.